Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006930 | 0.93 | LPL (0.40) | LPLLIPGESR2EGFRBACE1 | |
| SCHEMBL20794283 | 0.93 | LPL (0.40) | LPLLIPGESR2EGFRBACE1 | |
| SCHEMBL6924366 | 0.90 | EGFR (0.39) | LPLLIPGESR2EGFRBACE1 | |
| SCHEMBL20794291 | 0.86 | LPL (0.43) | LPLLIPGESR2EGFRROCK1 | |
| SCHEMBL2652740 | 0.83 | LPL (0.38) | LPLLIPGESR2EGFRBACE1 | |
| SCHEMBL2650626 | 0.82 | LPL (0.41) | LPLLIPGESR2EGFRROCK1 | |
| SCHEMBL2659727 | 0.81 | LPL (0.46) | LPLLIPGESR2EGFRROCK1 | |
| SCHEMBL15810291 | 0.81 | LPL (0.48) | LPLLIPGESR2EGFRROCK1 | |
| SCHEMBL6216928 | 0.80 | LPL (0.38) | LPLLIPGESR2EGFRROCK1 | |
| SCHEMBL20904725 | 0.79 | LPL (0.49) | LPLLIPGEGFRROCK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11600783-B2 | Organic molecules for use in optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-03-07 | — | — | US | disclosed |
| EP-3672956-B1 | ORGANIC TRIAZINE CONTAINING MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-20200235308-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-07-23 | — | — | US | disclosed |
| WO-2019063288-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELCTRONIC DEVICES | CYNORA GMBH (DE) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019038448-A1 | ORGANIC TRIAZINE CONTAINING MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. (GB) | 2004-09-02 | — | — | US | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200235308-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OXER1, OR10J3, OXGR1 | LPL 4853/4885LIPG 4281/4885ESR2 383/4885 |
| US-11600783-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OR51E2, ALDH1A2 | LPL 4686/4885LIPG 2272/4885ESR2 862/4885 |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | GABRA1, GABRA4, GABRA6 | LPL 3649/4885LIPG 4342/4885ESR2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.